Confidential materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote such omission.
Exhibit 10.2
Private & Confidential
Execution Copy
DATED AS OF JUNE 21, 2006
CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED (1)
and
DYAX CORP. (2)
AMENDED AND RESTATED LICENCE AGREEMENT
THIS AGREEMENT is made as of June 21, 2006
BETWEEN:
(1) CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED (Registered in England No. 2451177)
whose registered office is at The Milstein Building, Granta Park, Cambridge, Cambridgeshire, CB1 6GH,
UK (“ CAT ”).
(2) DYAX CORP. a corporation organised and existing under the laws of the State of Delaware having its
principal place of business at 300 Technology Square, Cambridge, Massachusetts 02139 USA (“ Dyax
”).
BACKGROUND:
(a) The Parties entered into the Original Agreements; an Amendment Agreement and a Second Amendment
Agreement (as defined below) regarding the use of their respective rights in (b) and (c) below.
(b) CAT is the owner or exclusive licensee (pursuant to an agreement dated 7 January 1997 between CAT
and the Medical Research Council (“ MRC ”)) of the CAT Antibody Phage Display Patents (as defined
below).
(c) Dyax has the right to grant licenses to certain technology described and claimed in US Patent No.
THIS AGREEMENT is made as of June 21, 2006
BETWEEN:
(1) CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED (Registered in England No. 2451177)
whose registered office is at The Milstein Building, Granta Park, Cambridge, Cambridgeshire, CB1 6GH,
UK (“ CAT ”).
(2) DYAX CORP. a corporation organised and existing under the laws of the State of Delaware having its
principal place of business at 300 Technology Square, Cambridge, Massachusetts 02139 USA (“ Dy